CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Maziar Doustdar

President and Chief Executive Officer (CEO), Novo Nordisk

Search every verified Maziar Doustdar interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In August 2026, Novo Nordisk President and CEO Maziar "Mike" Doustdar discussed the company's obesity treatments and market competition in interviews with Reuters and CNBC's Jim Cramer. Doustdar stated that GLP-1 medications such as Wegovy are treatments for obesity, not a cure, and said that many patients regain weight after discontinuing the medication. He compared this to treatments for other chronic conditions, such as statins for high cholesterol or insulin for diabetes. Doustdar also said that increasing affordability and patient education could help patients remain on these treatments longer. Doustdar also addressed competition with Eli Lilly's Zepbound, saying that both Wegovy and Zepbound reduce weight similarly but that Wegovy's label includes proven reductions in risk of heart attack, stroke, and kidney and liver benefits. He advised patients to consult their physicians to choose the appropriate drug. Regarding Eli Lilly's advertising, Doustdar said the company's claims were truthful but not the complete picture, citing Novo Nordisk's Wegovy high-dose product with efficacy on par with its competitor. He also discussed the launch of the Wegovy pill, noting that it had been prescribed more than 5 million times, and mentioned an upcoming combination therapy, CagriSema, which he said would be the first amylin combo product launched by any pharmaceutical company.

Recent appearances

  • Novo Nordisk CEO On Wegovy: “These Drugs Are Treatments, Not A Cure” | N18G

    August 13, 2026 · 📺 CNBC-TV18

    Novo Nordisk CEO Maziar “Mike” Doustdar says the rapidly growing obesity-drug market will become increasingly competitive, with patients looking beyond weight loss when choosing treatments. In an interview with Reuters, Doustdar stressed that Wegovy and other GLP-1 medicines are treatments for obesity, not a cure, arguing that many patients regain weight after stopping medication. Doustdar also discussed the competition between Wegovy and Eli Lilly’s Zepbound, saying patients should consult their doctors about differences between the drugs and their potential health benefits. He highlighted No…

    Watch on YouTube ↗

  • Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer

    August 12, 2026 · 📺 CNBC Television

    Novo Nordisk President and CEO Mike Doustdar joins 'Mad Money' host Jim Cramer to talk quarterly results, launching its GLP-1 pill, competition in the weight-loss drug space, and more. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/42d859g » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Watch CNBC on the go with CNBC+: https://www.cnbc.com/WatchCNBCPlus Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business…

    Watch on YouTube ↗

  • Novo Nordisk CEO addresses investors' high Wegovy pill expectations

    August 05, 2026 · 📺 CNBC International Live

    Novo Nordisk hikes its 2026 outlook, but investors focus more on quarterly sales of the Danish pharma giant's Wegovy weight loss pill, which came in slightly lower than expected. CEO Mike Doustdar addresses the expectations in a first on CNBC interview with Carolin Roth.

    Watch on YouTube ↗

  • Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before

    June 09, 2026 · 📺 CNBC Television

    At the American Diabetes Association’s 2026 Scientific Sessions, CNBC’s Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss the launch of the Wegovy pill and how it became the best prescription drug launch in history.

    Watch on YouTube ↗

  • Novo Nordisk CEO: We are a cardiometabolic powerhouse

    June 09, 2026 · 📺 CNBC Television

    At the American Diabetes Association’s 2026 Scientific Sessions, CNBC’s Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss what to expect from Novo’s pipeline and strategy in the years to come. “We're going to be very diversified,” he says. “But all of it within the area of cardiometabolics, per se. Diabetes, obesity, cardiometabolic, and some of the adjacencies.”

    Watch on YouTube ↗

  • Novo Nordisk CEO: Open to deals, we need the broadest pipeline in the world

    May 06, 2026 · 📺 CNBC Television

    CNBC’s Angelica Peebles speaks with Novo Nordisk CEO Mike Doustdar about the company’s quarterly report, the strong launch of the Wegovy pill and what else Novo Nordisk has to come in the pipeline. He says he’s always open to doing deals that will strengthen the portfolio and it’s part of the company’s mindset not to become to complacent or arrogant about Novo’s “fantastic” pipeline as it stands. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/42d859g » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/Subsc…

    Watch on YouTube ↗

  • Novo Nordisk CEO: This is where science meets speed and scale

    April 14, 2026 · 📺 CNBC Television

    Maziar Mike Doustdar, CEO of Novo Nordisk, says AI partnership with OpenAI will speed drug discovery and delivery, boost accuracy and strengthen confidence in Wegovy despite rising competition. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/42d859g » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Watch CNBC on the go with CNBC+: https://www.cnbc.com/WatchCNBCPlus Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in…

    Watch on YouTube ↗

  • IN FULL: Mike Doustdar Addresses the National Press Club of Australia

    March 16, 2026 · 📺 National Press Club of Australia

    Mike Doustdar, President and CEO of Novo Nordisk, Addresses the National Press Club of Australia on “How Australia Can Lead the World Against Chronic Disease”. Website: www.npc.org.au Instagram: @pressclubaust Facebook: @NationalPressClubofAustralia X: @PressClubAust

    Watch on YouTube ↗

  • Novo Nordisk CEO on medicare coverage, new obesity pill, U.S. pricing pressure

    February 13, 2026 · 📺 CNBC Television

    Novo Nordisk CEO Mike Doustdar tells CNBC that Medicare coverage for obesity treatments, as well as the launch of a new obesity pill, should help boost prescription volumes and offset lower prices. Chapters: 00:00 Introduction 00:31 Novo Nordisk’s 2026 Outlook  6:51 EU Regulations 12:36 DOJ and FDA Support 14:41 Medical Coverage 20:00 Market share Reporter: Annika Kim Constantino Producer: Darren Geeter Senior Managing Producer: Tala Hadavi Camera by: Tara McCurrie and Shawn McMillan Audio by: Francesco LoCascio For access to live and exclusive video from CNBC subscribe to CNBC PRO: http…

    Watch on YouTube ↗

  • Novo Nordisk CEO on Hims Suit, Wegovy Demand and Pricing

    February 11, 2026 · 📺 Bloomberg Television

    Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg’s Katie Greifeld to discuss GLP-1 supply, pricing and the company’s lawsuit against Hims over alleged obesity drug copycats. -------- More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9 Visit http://www.bloomberg.com for business news & analysis, up-to-the-minute market data, features, profiles and more. Connect with Bloomberg Tel…

    Watch on YouTube ↗

  • Novo Nordisk CEO addresses U.S. headwinds after guidance shock

    February 04, 2026 · 📺 CNBC International Live

    Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate price pressures throughout 2026.

    Watch on YouTube ↗

  • The Readout LOUD live from JPM26

    January 14, 2026 · 📺 STAT

    How did an office clerk become CEO of a major pharmaceutical company? What’s “Project Prometheus”? And what’s next in drug R&D? Allison, Adam, and Elaine are asking those questions live from the J.P. Morgan Healthcare Conference in San Francisco. Then, ARCH Venture Partners co-founder and managing director Bob Nelsen takes the mic to discuss everything going on in D.C., China’s ascent in biomedical innovation, and the use of AI in biotech. New Novo Nordisk CEO Mike Doustdar joins the podcast hosts live to discuss his first few months on the job and the company’s push to regain market share…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →